Eplivanserin
Chemical compound / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Eplivanserin?
Summarize this article for a 10 year old
SHOW ALL QUESTIONS
Eplivanserin (SR-46,349; planned trade name Ciltyri) was an experimental drug for the treatment of insomnia which was being developed by Sanofi Aventis.[1]
Quick Facts Clinical data, Routes ofadministration ...
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider |
|
UNII | |
KEGG |
|
ECHA InfoCard | 100.189.857 |
Chemical and physical data | |
Formula | C19H21FN2O2 |
Molar mass | 328.387 g·mol−1 |
3D model (JSmol) | |
| |
| |
NY (what is this?) (verify) |
Close
Sanofi Aventis announced in December 2009 that it was withdrawing its application for approval of eplivanserin from both the U.S. Food and Drug Administration and the European Medicines Agency.[2]